Edition:
India

Integra LifeSciences Holdings Corp (IART.OQ)

IART.OQ on NASDAQ Stock Exchange Global Select Market

49.98USD
2:22am IST
Change (% chg)

$0.96 (+1.96%)
Prev Close
$49.02
Open
$49.13
Day's High
$50.00
Day's Low
$48.86
Volume
105,089
Avg. Vol
187,187
52-wk High
$56.39
52-wk Low
$40.51

Latest Key Developments (Source: Significant Developments)

Integra Lifesciences Holdings Corp ‍Reaffirms 2017 Financial Guidance As Provided On Oct 26, 2017​
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Integra Lifesciences Holdings Corp ::- ‍REAFFIRMING 2017 FINANCIAL GUIDANCE AS PROVIDED ON OCTOBER 26, 2017​.- ‍REAFFIRMING 2018 ADJUSTED EARNINGS PER SHARE IN RANGE OF $2.25 TO $2.35​.INTEGRA LIFESCIENCES SAYS PROVIDING 2018 PRELIMINARY REVENUE ESTIMATE IN RANGE OF $1.46 BILLION TO $1.48 BILLION - SEC FILING.INTEGRA LIFESCIENCES - ESTABLISHING FIVE-YEAR FINANCIAL TARGETS OF ABOUT $2 BILLION IN REVENUE AND AN ADJUSTED EBITDA MARGIN RANGE OF 28% TO 30%.FY2018 EARNINGS PER SHARE VIEW $2.30 -- THOMSON REUTERS I/B/E/S.FY2017 EARNINGS PER SHARE VIEW $1.85, REVENUE VIEW $1.17 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Capital Research Global Investors Reports 11.1 Pct Passive Stake In Integra Lifesciences As Of Nov 30
Saturday, 9 Dec 2017 

Dec 8 (Reuters) - Integra Lifesciences Holdings Corp ::CAPITAL RESEARCH GLOBAL INVESTORS REPORTS 11.1 PERCENT PASSIVE STAKE IN INTEGRA LIFESCIENCES HOLDINGS CORP AS OF NOVEMBER 30 - SEC FILING.  Full Article

Integra Lifesciences Q3 adjusted earnings per share $0.45
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Integra Lifesciences Holdings Corp ::Integra Lifesciences reports third quarter 2017 financial results.Q3 adjusted earnings per share $0.45.Q3 GAAP earnings per share $0.04.Q3 revenue $279 million versus I/B/E/S view $286.1 million.Q3 earnings per share view $0.47 -- Thomson Reuters I/B/E/S.Sees FY 2017 adjusted earnings per share $1.83 to $1.87.Sees FY 2017 gaap earnings per share $0.24 to $0.30.Sees FY 2017 revenue $1.165 billion to $1.175 billion.Integra Lifesciences Holdings Corp - "‍we expect some storm-related disruptions to continue to impact revenues in Q4"​.Integra Lifesciences Holdings Corp - ‍full-year 2017 organic revenue growth is now expected to be about 4 pct​.FY2017 earnings per share view $1.91, revenue view $1.15 billion -- Thomson Reuters I/B/E/S.  Full Article

Integra Lifesciences says Depuy Synthes entitled to get termination fee of $60 million if co fails to complete deal
Wednesday, 15 Feb 2017 

Integra Lifesciences Holdings Corp : Depuy Synthes entitled to get termination fee of $60 million if co fails to complete deal after conditions to closing are satisfied .Depuy Synthes to pay termination fee of $41.8 million if co terminates deal due to Depuy Synthes’S breach of exclusivity obligations.  Full Article

Integra Lifesciences plans to acquire Codman neurosurgery business from Johnson & Johnson for $1.045 bln
Wednesday, 15 Feb 2017 

Integra Lifesciences Holdings Corp : Integra Lifesciences plans to acquire the Codman neurosurgery business from Johnson & Johnson for $1.045 billion in cash . Deal for $1.045 billion in cash . Transaction expected to be accretive to integra's adjusted earnings per diluted share by at least $0.22 in first fy . Says expects codman neurosurgery revenue to experience some initial disruption in first year of combination . Says expects codman neurosurgery revenue to grow 3% to 6% longer term . Says has obtained committed financing, subject to customary closing conditions, from BofA Merrill Lynch and JPMorgan .Deal expected to also accelerate path to achieving co's aspirational targets of $2 billion in revenue, 30% adjusted ebitda margin.  Full Article

Integra Lifesciences sees 2016 sales $992 mln-$1.002 bln
Thursday, 28 Jul 2016 

Integra Lifesciences Holdings Corp : Raising its FY gaap and adjusted eps guidance by $0.04/share and narrowing guidance range to new range of $1.78 - $1.88 and $3.43 - $3.53, respectively . Integra lifesciences reports second quarter 2016 financial results . Q2 adjusted earnings per share $0.79 . Q2 gaap earnings per share $0.32 . Q2 revenue $249.3 million versus i/b/e/s view $243.2 million . Sees fy 2016 sales $992 million to $1.002 billion . Q2 earnings per share view $0.76 -- Thomson Reuters I/B/E/S . Integra lifesciences holdings corp says q2 gaap gross margin was 64.1% and adjusted gross margin was 69.2% . Integra lifesciences holdings corp says raising organic sales guidance to 9%. For 2016 .FY2016 earnings per share view $3.44, revenue view $994.8 million -- Thomson Reuters I/B/E/S.  Full Article

Integra Lifesciences Holdings Corp raises low end of prior guidance range
Wednesday, 27 Apr 2016 

Integra Lifesciences Holdings Corp:Raising low end of FY 2016 revenue guidance to a new range of $985 million to $1.0 billion, up from prior guidance of $975 million to $1.0 billion.Raises Fy 2016 organic revenue growth to about 8% from its previous guidance of about 7%.Adjusts low end of its FY 2016 adjusted earnings per share guidance range to $3.38 - $3.50 from $3.35 - $3.50.Says the company's GAAP EPS guidance is now $1.73 to $1.85.  Full Article

Integra LifeSciences Holdings Corp announces Service Alliance Agreement With PREZIO Health
Friday, 26 Feb 2016 

Integra LifeSciences Holdings Corp:Integra Lifesciences announces service alliance agreement with prezio health.Says prezio health will act as integra's authorized surgical instruments service provider.  Full Article

Integra LifeSciences Receives FDA Approval of Integra Dermal Regeneration Template (IDRT) for Treatment of Chronic Diabetic Foot Ulcers (DFU)
Friday, 8 Jan 2016 

Integra LifeSciences Holdings Corporation:Says United States Food and Drug Administration (FDA) has approved the PMA Supplement for Integra Dermal Regeneration Template (IDRT) for treatment of diabetic foot ulcers (DFU).approval of this new indication is based on results from the FOUNDER (FOot Ulcer New DErmal Replacement) Study, a multi-center, randomized, controlled, parallel group clinical trial conducted under an Investigational Device Exemption (IDE).FOUNDER Study showed that patients treated with IDRT demonstrated a 59% improvement in incidence of complete wound closure compared to standard of care.IDRT, with its newly approved DFU indication, will be marketed under the name Integra Omnigraft Dermal Regeneration Template.  Full Article